TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $46.00.

Several research analysts recently weighed in on TMDX shares. Morgan Stanley upped their price target on TransMedics Group from $34.00 to $37.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 3rd. Canaccord Genuity Group upped their price target on TransMedics Group from $46.00 to $58.00 in a research report on Thursday, August 4th. Cowen upped their price target on TransMedics Group from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, July 26th. Oppenheimer upped their price target on TransMedics Group from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. raised TransMedics Group from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd.

Insiders Place Their Bets

In other news, VP John F. Carey sold 2,956 shares of the stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $32.57, for a total transaction of $96,276.92. Following the transaction, the vice president now owns 379 shares of the company’s stock, valued at approximately $12,344.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, VP John F. Carey sold 2,956 shares of the stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $32.57, for a total transaction of $96,276.92. Following the transaction, the vice president now owns 379 shares of the company’s stock, valued at approximately $12,344.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 12,929 shares of the stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $46.74, for a total value of $604,301.46. Following the transaction, the chief executive officer now directly owns 493,285 shares in the company, valued at approximately $23,056,140.90. The disclosure for this sale can be found here. Insiders have sold a total of 183,905 shares of company stock valued at $7,240,928 in the last three months. Insiders own 8.70% of the company’s stock.

Institutional Trading of TransMedics Group

Several hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its stake in TransMedics Group by 3.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 15,550 shares of the company’s stock valued at $489,000 after purchasing an additional 450 shares during the period. Park Avenue Securities LLC lifted its position in shares of TransMedics Group by 3.3% in the 2nd quarter. Park Avenue Securities LLC now owns 17,505 shares of the company’s stock worth $551,000 after acquiring an additional 560 shares during the period. Legal & General Group Plc lifted its position in shares of TransMedics Group by 4.9% in the 2nd quarter. Legal & General Group Plc now owns 13,502 shares of the company’s stock worth $425,000 after acquiring an additional 631 shares during the period. Advisor Group Holdings Inc. lifted its position in shares of TransMedics Group by 7.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 13,173 shares of the company’s stock worth $354,000 after acquiring an additional 948 shares during the period. Finally, FNY Investment Advisers LLC bought a new stake in shares of TransMedics Group in the 2nd quarter worth approximately $31,000. Institutional investors own 81.46% of the company’s stock.

TransMedics Group Trading Down 5.7 %

Shares of TMDX stock opened at $47.55 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.41 and a current ratio of 4.18. TransMedics Group has a 1 year low of $10.00 and a 1 year high of $56.41. The stock has a fifty day moving average of $45.27 and a two-hundred day moving average of $32.87. The firm has a market capitalization of $1.34 billion, a PE ratio of -27.65 and a beta of 1.48.

TransMedics Group (NASDAQ:TMDXGet Rating) last announced its quarterly earnings data on Monday, August 1st. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.09). TransMedics Group had a negative net margin of 92.76% and a negative return on equity of 74.20%. The firm had revenue of $20.52 million during the quarter, compared to analyst estimates of $16.26 million. During the same quarter last year, the company earned ($0.39) EPS. As a group, research analysts expect that TransMedics Group will post -1.57 EPS for the current year.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Analyst Recommendations for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.